# Novo Nordisk Novo Nordisk is an Asset Manager based in Bagsvaerd, Denmark. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Bagsvaerd, Denmark - **Region:** Europe - **Address:** Bagsvaerd, Denmark - **Founded:** 1923 - **Assets under management:** Undisclosed - **Website:** novonordisk.com - **LinkedIn:** https://www.linkedin.com/company/novo-nordisk ## Regulatory record - **Reports private funds:** No ## About Novo Nordisk was founded in 1923 and is controlled by the Novo Nordisk Foundation, a Danish charitable foundation that holds the majority of voting shares — a governance structure unique among global pharmaceutical giants. Lars Fruergaard Jørgensen has served as CEO since 2017, steering the company through a historic demand surge for its GLP-1 receptor agonist products, semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda). The foundation model, originally established to ensure long-term independence, means the firm's strategic direction is insulated from quarterly shareholder pressure, enabling sustained investment in both manufacturing and early-stage research. Novo Nordisk operates exclusively in the pharmaceutical sector, with a strategy built on three therapeutic pillars: diabetes care, obesity care, and rare diseases. The company commits heavily to organic capital expenditure rather than financial-portfolio diversification, spending over $6 billion in 2023 alone on expanding fill-finish and active pharmaceutical ingredient (API) capacity in Denmark, France, and the United States. Its pipeline focuses on next-generation incretin therapies, including oral semaglutide and combination candidates like CagriSema, alongside gene therapies for hemophilia and growth disorders. Core markets include North America, Europe, and China, with manufacturing sites strategically distributed across Denmark, the US, Brazil, China, and France. Novo Nordisk employs over 60,000 people globally and reported total revenue of DKK 232.3 billion (approximately $33.8 billion) in 2023 (per the firm's 2023 annual report). The Novo Nordisk Foundation, which controls the company, is among the world's wealthiest charitable foundations, deploying grants primarily in scientific research, education, and humanitarian causes. March 2024: Announced a $4.1 billion investment to construct a second fill-finish manufacturing facility in Clayton, North Carolina, further addressing global Wegovy supply constraints (per the firm, March 2024). The genuine structural differentiator is the foundation ownership model. The Novo Nordisk Foundation holds approximately 77% of voting shares, a structure that decouples corporate strategy from conventional capital-market pressures and enables the firm to take decade-long views on manufacturing capacity and disease-area focus. This governance architecture, combined with an integrated business model — from API synthesis to final device assembly — creates barriers to entry that generic competitors and even well-capitalized biotech challengers struggle to overcome. ## Sectors - Pharmaceuticals - Diabetes & Obesity Care - Rare Diseases - Biotechnology ## People - Lars Fruergaard Jørgensen — President and CEO - Karsten Munk Knudsen — Executive Vice President and CFO ## Questions ### Who controls Novo Nordisk? The Novo Nordisk Foundation, a Danish charitable foundation, holds approximately 77% of the voting shares in Novo Nordisk A/S. This structure has been in place since 1923 and grants the foundation effective control over the company's board composition and long-term strategy. The foundation is one of the world's largest by assets, focused on scientific research and medical causes. ### What does Novo Nordisk manufacture beyond the GLP-1 obesity franchise? Novo Nordisk's manufacturing operations span insulin products (Tresiba, Fiasp), GLP-1 receptor agonists for type 2 diabetes (Ozempic, Rybelsus), obesity therapeutics (Wegovy, Saxenda), and treatments for rare endocrine disorders and hemophilia. The company also produces human growth hormone (Norditropin) and hormone replacement therapies, maintaining a diversified endocrine pipeline. ### Where are Novo Nordisk's primary manufacturing sites located? Active pharmaceutical ingredient (API) production is concentrated in Kalundborg, Denmark, and Clayton, North Carolina. Fill-finish operations — the final steps of formulation, filling, and device assembly — are distributed across Bagsværd and Hillerød (Denmark), Chartres (France), Tianjin (China), Montes Claros (Brazil), and multiple US sites including Durham and Clayton, North Carolina. ### Is Novo Nordisk involved in private equity, venture capital, or fund investing? Novo Nordisk A/S is a pharmaceutical manufacturer and does not operate a private equity or venture capital arm. The Novo Nordisk Foundation wholly owns Novo Holdings, a separate entity that manages the foundation's investment assets, including a substantial life-science venture and growth-equity portfolio. Novo Holdings, not the pharmaceutical company, is the vehicle through which endowment-style and venture investing occurs. ### What is the relationship between Novo Holdings and Novo Nordisk A/S? Novo Holdings A/S is the holding and investment company wholly owned by the Novo Nordisk Foundation. It manages approximately DKK 1 trillion in assets, including the foundation's controlling stake in Novo Nordisk A/S. Novo Holdings operates independently from the pharmaceutical company, with its own CEO and investment teams, focusing on equity investments in life-science and biotechnology companies globally. ## Related profiles - [Northern Border Advisors](https://altss.com/profile/northern-border-advisors-llc) - [Nowoption](https://altss.com/profile/nowoption) --- Last updated: 2026-07-06T00:36:43.925Z Canonical page: https://altss.com/profile/novo-nordisk Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology